Advertisement

Multiple myeloma, an incurable blood cancer, is the target of two separate clinical trials launched this week to study and treat the disease. While Wednesday saw the enrollment of the first person in a 1,000-patient study focused on personalized medicine strategies, today Acetylon Pharmaceuticals Inc. of Boston has begun a Phase 1-2a clinical trial of its multiple myeloma treatment, ACY-1215.

SOURCE

Advertisement
Advertisement